MIRMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Mirum Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$82.24+2.10 (+2.62%)
Close on Oct 19, 2026
- Market cap
- $5.21B
- P/E (TTM)
- –
- Dividend yield
- –
Mirum Pharmaceuticals, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -134.9%
- Net margin
- -139.2%
- Return on equity, FY2025
- -8.6%
Financial strength
- Current ratio
- 2.86
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 148.4%
Valuation
- P/E ratio
- –
- Price to sales
- 8.43
- Price to book
- –
- Dividend yield
- –